By Daniel Wilson ( September 1, 2015, 4:16 PM EDT) -- Eisai Inc. told a Washington, D.C., federal judge Tuesday that the U.S. Food and Drug Administration should be required to extend market exclusivity periods for an epilepsy drug and a weight-loss drug, saying the regulator had wrongly failed to take into account delays caused by required controlled substance reviews....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.